{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:39:33Z","timestamp":1761871173156,"version":"build-2065373602"},"reference-count":59,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.clml.2017.11.003","type":"journal-article","created":{"date-parts":[[2017,12,9]],"date-time":"2017-12-09T18:09:37Z","timestamp":1512842977000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT"],"prefix":"10.1016","volume":"18","author":[{"given":"Matthew","family":"Mei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2017.11.003_bib1","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMra1003733","article-title":"Early-stage Hodgkin's lymphoma","volume":"363","author":"Armitage","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2017.11.003_bib2","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1200\/JCO.2015.62.4817","article-title":"Long-term results of the HD2000 trial comparing ABVD versus BEACOPP versus COPP-EBV-CAD in untreated patients with advanced Hodgkin lymphoma: a study by Fondazione Italiana Linfomi","volume":"34","author":"Merli","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib3","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1200\/JCO.2000.18.2.332","article-title":"Treatment of primary progressive Hodgkin's and aggressive non-Hodgkin's lymphoma: is there a chance for cure?","volume":"18","author":"Josting","year":"2000","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib4","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1093\/annonc\/mdt206","article-title":"Identification of prognostic factors predicting outcome in Hodgkin's lymphoma patients relapsing after autologous stem cell transplantation","volume":"24","author":"Mart\u00ednez","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib5","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/sj.bmt.1705977","article-title":"Superiority of reduced-intensity allogeneic transplantation over conventional treatment for relapse of Hodgkin's lymphoma following autologous stem cell transplantation","volume":"41","author":"Thomson","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/bmt.2013.226","article-title":"Managing Hodgkin lymphoma relapsing after autologous hematopoietic cell transplantation: a not-so-good cancer after all!","volume":"49","author":"Kharfan-Dabaja","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib7","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/bmt.2015.332","article-title":"Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis","volume":"51","author":"Rashidi","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib8","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1200\/JCO.1985.3.11.1490","article-title":"Allogeneic marrow transplantation in the treatment of MOPP-resistant Hodgkin's disease","volume":"3","author":"Appelbaum","year":"1985","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib9","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","article-title":"Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation","volume":"365","author":"Peggs","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.11.003_bib10","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","article-title":"Allogeneic bone marrow transplant is not better than autologous transplant for patients with relapsed Hodgkin's disease. European Group for Blood and Bone Marrow Transplantation","volume":"14","author":"Milpied","year":"1996","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib11","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1200\/JCO.1993.11.12.2342","article-title":"Allogeneic, syngeneic, and autologous marrow transplantation for Hodgkin's disease: the 21-year Seattle experience","volume":"11","author":"Anderson","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib12","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","article-title":"Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma: an analysis from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"26","author":"Sureda","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib13","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","article-title":"Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Genadieva-Stavrik","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib14","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib15","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1182\/blood-2011-10-388058","article-title":"Normalization of pre-ASCT, FDG-PET imaging with second-line, non-cross-resistant, chemotherapy programs improves event-free survival in patients with Hodgkin lymphoma","volume":"119","author":"Moskowitz","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib16","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1016\/j.bbmt.2016.03.034","article-title":"Impact of pretransplantation 18F-fluorodeoxyglucose-positron emission tomography on survival outcomes after T cell\u2013depleted allogeneic transplantation for Hodgkin lymphoma","volume":"22","author":"Reyal","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib17","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1038\/bmt.2017.99","article-title":"Long-term follow-up of allogeneic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma","volume":"52","author":"Giaccone","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib18","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","article-title":"Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience","volume":"93","author":"Anderlini","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.003_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/ajh.23897","article-title":"The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"90","author":"Kako","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2017.11.003_bib20","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/j.1365-2141.2007.06759.x","article-title":"Reduced-intensity conditioning for allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes","volume":"139","author":"Peggs","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2017.11.003_bib21","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.bbmt.2008.01.008","article-title":"Allogeneic transplantation with reduced-intensity conditioning for Hodgkin and non-Hodgkin lymphoma: importance of histology for outcome","volume":"14","author":"Armand","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib22","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1016\/j.bbmt.2015.05.010","article-title":"The impact of graft-versus-host disease on the relapse rate in patients with lymphoma depends on the histological subtype and the intensity of the conditioning regimen","volume":"21","author":"Urbano-Ispizua","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib23","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-010-1146-3","article-title":"Reduced intensity allogeneic hematopoietic cell transplantation can induce durable remission in heavily pretreated relapsed Hodgkin lymphoma","volume":"90","author":"Chen","year":"2011","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2017.11.003_bib24","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.003_bib25","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/JCO.2007.15.8865","article-title":"Analysis of risk factors for outcomes after unrelated cord blood transplantation in adults with lymphoid malignancies: a study by the Eurocord-Netcord and Lymphoma Working Party of the European Group for Blood and Marrow Transplantation","volume":"27","author":"Rodrigues","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib26","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.3109\/10428194.2015.1105370","article-title":"Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma","volume":"57","author":"Thompson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2017.11.003_bib27","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.bbmt.2008.11.013","article-title":"Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation","volume":"15","author":"Brunstein","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib28","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/ejh.12557","article-title":"Umbilical cord blood transplantation in adults with advanced Hodgkin's disease: high incidence of post-transplant lymphoproliferative disease","volume":"96","author":"Pi\u00f1ana","year":"2016","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2017.11.003_bib29","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","article-title":"Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin's lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)","volume":"98","author":"Marcais","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2017.11.003_bib30","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/bmt.2016.349","article-title":"Reduced-intensity and non-myeloablative allogeneic stem cell transplantation from alternative HLA-mismatched donors for Hodgkin lymphoma: a study by the French Society of Bone Marrow Transplantation and Cellular Therapy","volume":"52","author":"Gauthier","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib31","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","article-title":"Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma","volume":"14","author":"Burroughs","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib32","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","article-title":"Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin's lymphoma","volume":"49","author":"Raiola","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib33","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/bmt.2016.348","article-title":"Haploidentical transplantation with post-infusion cyclophosphamide in advanced Hodgkin lymphoma","volume":"52","author":"Castagna","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib34","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2017.01.079","article-title":"Human leukocyte antigen-haploidentical transplantation for relapsed\/refractory Hodgkin lymphoma: a multicenter analysis","volume":"23","author":"Pitombeira de Lacerda","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib35","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1200\/JCO.2015.66.3476","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors: a Center for International Blood and Marrow Transplant Research analysis","volume":"34","author":"Ghosh","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1182\/blood-2015-09-671834","article-title":"Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors","volume":"127","author":"Kanate","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib37","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Mart\u00ednez","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib38","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40259-013-0077-7","article-title":"Management of relapsed or refractory Hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin","volume":"28","author":"Mei","year":"2014","journal-title":"Biodrugs"},{"key":"10.1016\/j.clml.2017.11.003_bib39","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib40","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2017.11.003_bib41","doi-asserted-by":"crossref","first-page":"6379","DOI":"10.1182\/blood-2012-03-418673","article-title":"Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma","volume":"119","author":"Chen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib42","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","article-title":"Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma","volume":"20","author":"Chen","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib43","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2119","article-title":"Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin's lymphoma","volume":"32","author":"Garciaz","year":"2014","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib44","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/1756-8722-7-24","article-title":"Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies","volume":"7","author":"Bartlett","year":"2014","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib45","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","article-title":"Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma","volume":"128","author":"Chen","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib46","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","article-title":"Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib47","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib48","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib49","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1182\/blood-2016-09-738385","article-title":"Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed\/refractory lymphoma","volume":"129","author":"Merryman","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib50","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1182\/blood.V128.22.1110.1110","article-title":"Checkmate 205 update with minimum 12-month follow up: a phase 2 study of nivolumab in patients with relapsed\/refractory classical Hodgkin lymphoma","volume":"128","author":"Timmerman","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib51","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1016\/j.bbmt.2011.02.009","article-title":"Relapse of lymphoma after allogeneic hematopoietic cell transplantation: management strategies and outcome","volume":"17","author":"Wudhikarn","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib52","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1200\/JCO.2012.43.6832","article-title":"Brentuximab vedotin combined with donor lymphocyte infusions for early relapse of Hodgkin lymphoma after allogeneic stem-cell transplantation induces tumor-specific immunity and sustained clinical remission","volume":"31","author":"Theurich","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib53","doi-asserted-by":"crossref","first-page":"4361","DOI":"10.1182\/blood.V126.23.4361.4361","article-title":"Brentuximab vedotin in combination with donor lymphocyte infusion for patients with Hodgkin lymphoma relapsing after allogeneic stem cell transplantation","volume":"126","author":"Tsirigotis","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib54","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/sj.bmt.1704621","article-title":"Donor leukocyte infusions in relapsed Hodgkin's lymphoma following allogeneic stem cell transplantation: CD3+ cell dose, GVHD and disease response","volume":"34","author":"Anderlini","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib55","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","article-title":"Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell\u2013depleted allogeneic transplantation for Hodgkin's lymphoma","volume":"29","author":"Peggs","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2017.11.003_bib56","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.bbmt.2005.09.009","article-title":"Nonmyeloablative stem cell transplantation is an effective therapy for refractory or relapsed Hodgkin lymphoma: results of a Spanish prospective cooperative protocol","volume":"12","author":"Alvarez","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2017.11.003_bib57","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/blood-2017-01-761346","article-title":"PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD","volume":"130","author":"Haverkos","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib58","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","article-title":"Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma","volume":"129","author":"Herbaux","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2017.11.003_bib59","doi-asserted-by":"crossref","unstructured":"Chen R, Gibb A, Collins. GP, et\u00a0al. Blockade of the PD-1 checkpoint with anti\u2013PD-L1 avelumab is sufficient for clinical activity in relapsed\/refractory classical Hodgkin lymphoma (cHL). Presented at the 14th International Conference on Malignant Lymphoma, June 14-17, 2017, Lugano, Switzerland.","DOI":"10.1002\/hon.2437_54"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308820?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265017308820?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:31:23Z","timestamp":1761870683000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265017308820"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S2152265017308820"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.003","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How to Approach a Hodgkin Lymphoma Patient With Relapse After Autologous SCT: Allogeneic SCT","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2017.11.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}